Abstracts tagged "Treg cells"

Abstract Number: 1001 • ACR Convergence 2025
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Hongyan Shang¹, Xiao Huang², Duqing Jiang¹, Jianming Sun², Yurong Qin², Guojin Wu², Chengze Ni¹, Jing Guan², Jordan Zhu³, Xiaoqiang Kang² and Hong Ling², ¹Nanjing Leads Biolabs Co., Ltd., nanjing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ³Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Programmed cell death protein 1 (PD-1) is expressed on activated T cells and serves as a key co-inhibitory checkpoint molecule in immune regulation. Aberrant…
Abstract Number: 0992 • ACR Convergence 2025
FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
Laura J. Yockey¹, Ian Doyle², Thomas Guy³, Devanshi Trivedi², Chinmay Gadiraju⁴, Federica Bonaso⁵, Jesse Akaa², Alison Puri⁶, Zachary Wallace⁷, Guy Katz⁸, Sydney Montesi⁸, John Stone⁹, Flavia Castelino⁸, Shiv Pillai¹⁰, Andrew Luster¹¹, Vinay S. Mahajan¹² and Cory Perugino¹³, ¹MGH, Charlestown, MA, ²Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, ³Ragon Institute of MGH, MIT and Harvard/ Royal Prince Alfred Hospital Sydney, Sydney, Australia, ⁴Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ⁵University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ⁶Boston University, Brookline, MA, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital, Boston, MA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ¹⁰Harvard Medical School, Cambridge, MA, ¹¹Massachusetts General Hospital, Charlestown, MA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The absence of regulatory T cells (Tregs) results in multiorgan autoimmunity in the context of monogenic “Tregopathies,” but their role in mediating polygenic autoimmune…
Abstract Number: 0987 • ACR Convergence 2025
S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
Julia Manasson¹, Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: S-4321 is a novel antibody that agonizes the inhibitory PD-1 checkpoint receptor on T cells without competing for binding with its natural ligand, PD-L1,…
Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Christopher Moore¹, Travis Drow², Peter Cook², Annaiz Grimm², Victoria DeVault-Nelson¹, Jennifer Mellen¹, Payam Zarin¹, Alaina Burgess¹, Maegan Hoover¹, Tingxi Guo¹, Brock McKinney², Noelle Dahl², Aesha Vakil², Brian Christin³, Gene Uenishi¹, Tiffany Chen¹, Alberto Del Rio-Espinola⁴, David Rawlings² and Tom Wickham¹, ¹GentiBio, Cambridge, ²SCRI, Seattle, ³GentiBio, Seattle, ⁴GentiBio, Basel, Switzerland
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
Abstract Number: 0978 • ACR Convergence 2025
IL-17A+ HLA-DR-CCR6+ regulatory T cells: Dual role in T cell suppression and synovial inflammation in arthritis.
Bennie Heeswijk¹, Margot Bongenaar¹, Nadine Davelaar¹, Pascal de Jong¹, Hannah den Braanker¹, Radboud Dolhain¹ and Erik Lubberts², ¹Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ²Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Regulatory T cells (Tregs) are essential for maintaining immune tolerance and limiting excessive immune responses. However, Tregs show high levels of heterogeneity and plasticity,…
Abstract Number: 0501 • ACR Convergence 2025
Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
Sarah Baxter¹, Ari Bitton², Victor Yuan², Fawad Aslam³, Gregory Challener⁴, Jonathan Graf⁵, Melissa Griffith⁶, Tamiko Katsumoto⁷, Minna Kohler⁸, Elena Massarotti⁹, Larry Moreland¹⁰, Allison Rosenthal¹¹, Jeffrey Sparks⁹, Steven Vlad¹², Janeth Yinh¹³, Andrew Clauw¹⁴, Sally Arai¹⁵, Alexander Carvidi⁵, Angela Chavez¹⁶, Olivia Gabriel¹⁷, Rita Gyurko¹⁷, Megan Hall¹⁸, Jennifer Seifert¹⁹, Emma Stainton¹⁵, Michelle Blake¹, Sabrina Fox-Bosetti², Mark Fromhold¹, Mindy Jensen²⁰, Herve Lebrec², Sean O'Bryan², Amanda Pace²¹, Mei-Lun Wang², Yuanyuan Xiao², Joseph Arron² and Jeffrey Bluestone²², ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, San Francisco, CA, ³Mayo Clinic, Arizona, Scottsdale, AZ, ⁴MGH, Boston, MA, ⁵UCSF, San Francisco, CA, ⁶University of Colorado, Aurora, CO, ⁷Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mayo Clinic, Phoenix, ¹²Tufts Medicine, Boston, MA, ¹³Massachusetts General Hospital, Boston, MA, ¹⁴Univ of Colorado, Aurora, CO, ¹⁵Stanford, Palo Alto, CA, ¹⁶Tufts, Boston, MA, ¹⁷BWH, Boston, MA, ¹⁸Mayo, Scottsdale, AZ, ¹⁹University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ²⁰Sonoma Bio, Seattle, ²¹Sonoma Bio, Seattle, WA, ²²Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, and promote tissue repair, and thus hold promise as a versatile therapeutic tool. Autologous polyclonal Tregs…
Abstract Number: 0482 • ACR Convergence 2025
R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients
Christian Furlan Freguia¹, Janet Stephens¹, Sathya Janardhanan¹, Chuck Bourne¹, Kaitlyn Skeie¹, Hudson Lowe¹, David Pascual² and Gary Fanger¹, ¹Rise Therapeutics, Rockville, MD, ²University of Wyoming, Laramie, WY
Background/Purpose: R-2487 is a novel, orally delivered, synthetic biology-based immunotherapy that utilizes Lactococcus lactis as a carrier vehicle to deliver Colonization Factor Antigen I (CFA/I)…
Abstract Number: 0106 • ACR Convergence 2025
Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis
Goh Murayama¹, Kurisu Tada², Naoto Tamura³, Eri Hayashi¹, Taiga Kuga⁴, Ken Yamaji⁵ and HOSHIKO FURUSAWA⁶, ¹Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, ³Juntendo University School of Medicine, Tokyo, Japan, ⁴Juntendo University, Tokyo, Japan, ⁵Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ⁶juntendo, tokyo, Japan
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by enthesitis in axial joints, bone erosion near the entheses, and subsequent irreversible ankylosis due…
Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
Abstract Number: 2277 • ACR Convergence 2025
Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
John Bui¹, Jason Dubovsky², Jennifer Abrams³, Sara Charmsaz⁴, Michelle Blake¹, Joshua Beilke⁴, Anne-Renee van der Vuurst de Vries¹, Joseph Arron⁵, Jonathan Graf⁶ and Jeffrey Bluestone⁷, ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, South San Francisco, ³Sonomabio, San Francisco, CA, ⁴Sonoma Biotherapeutics, Seattle, ⁵Sonoma Biotherapeutics, San Francisco, CA, ⁶UCSF, San Francisco, CA, ⁷Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Emerging cell-based therapies for rheumatoid arthritis (RA) target the underlying immunologic activity of disease. Objective biomarkers to-date are downstream sequelae of RA immunologic drivers.…
Abstract Number: 1810 • ACR Convergence 2025
Destabilized Treg Cells Predominant in Severe Forms of Juvenile Idiopathic Arthritis
Ki Pui Lam¹, Claudia Harris², Jennifer Cheng³, Lwiza AitDowd⁴, Maryam Ashoor⁵, Ahmad Bakhsh³, Carrie Bryant³, Siobhan Case⁶, Mia Chandler³, Joyce Chang³, Ezra Cohen⁷, Fatma Dedeoglu³, Olha Halyabar⁸, Jonathan Hausmann⁹, Melissa Hazen³, Sonia Iosim¹⁰, Liyoung Kim¹¹, Jeffrey Lo³, Mindy Lo³, Emma Materne³, Esra Meidan¹², Megan Perron¹³, Helene Powers¹⁰, Mary Beth Son³, Holly Wobma³, Margaret Chang³, Pui Lee¹⁴, Peter Nigrovic¹¹ and Lauren Henderson¹⁵, ¹Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Childrens Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Brookline, MA, ⁶UpToDate, Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁷Bmc, NEEDHAM, MA, ⁸Children's Hospital/Boston Medical Center, Newton, MA, ⁹Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ¹⁰Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ¹¹Boston Children's Hospital, Brookline, MA, ¹²Boston Children's Hospital, Somerville, MA, ¹³Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Natick, MA, ¹⁴Boston Children's Hospital, Newton, MA, ¹⁵Boston Children's Hospital, Watertown, MA
Background/Purpose: T peripheral helper (Tph) cells stimulate excessive B cell responses in the joints of patients with autoantibody-positive arthritis, including seropositive RA in adults and…
Abstract Number: 1797 • ACR Convergence 2025
SEV-101 Exosomes Isolated from Induced Pluripotent Stem Cell – Derived Hyaline Cartilage Tissue – Characterization of Immunomodulatory and Chondro-proliferative Effects In Vitro
Parthasarathy Rangarajan¹, Beth Lindborg², Amanda Vegoe³, Yi Wen Chai⁴, Anna Tran¹, Magie Steinhoff¹, Bernhard Hering¹, Timothy O'Brien⁵ and Sabarinathan Ramachandran⁶, ¹Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, ²Sarcio, Inc., St. Paul, ³Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, St. Paul, ⁴Stem Cell Institute, University of Minnesota, Minneapolis, ⁵Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, Minneapolis, ⁶Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, MN
Background/Purpose: SEV-101 are exosomes that are isolated from cultures of Induced Pluripotent Stem Cell (iPSC)-derived hyaline cartilage tissue. Gene expression profiles of the tissue are…
Abstract Number: 1758 • ACR Convergence 2025
Treg need a MAIT: Investigating the contribution of MAIT cells to impaired UV-induced Treg expansion in lupus photosensitive reactions
Grace Crossland¹, Lindsay Mendyka¹, Vianey Chavez¹, Kaitlyn Dowling¹, Michael Constantinides² and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Scripps, La Jolla
Background/Purpose: Most systemic lupus erythematosus (SLE) patients experience sensitivity to ultraviolet (UV) light, which can trigger disfiguring skin lesions or systemic flares. In healthy skin,…
Abstract Number: 1756 • ACR Convergence 2025
Exosomal Cargo and Surface Markers: Informative Signals in Axial Spondyloarthritis
Fataneh Tavasolian¹, star lively², chiara Pastrello³, Melissa Lim¹, Addison Pacheco⁴, Zoya Qaiyum⁵, Michael Tang⁴, Zeynep Baskurt³, Igor Jurisica⁶, Mohit Kapoor⁵ and Robert Inman⁴, ¹University of Toronto, Toronto, ON, Canada, ²University Heaklth Network, Toronto, ³University Health Network, Toronto, ⁴University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶University Health Network, Toronto, Canada
Background/Purpose: Exosomes are small extracellular vesicles carrying surface molecules and molecular cargo, including microRNAs (miRNAs), that mediate intercellular communication. Both the exosomal cargo and surface…
Abstract Number: 1622 • ACR Convergence 2025
Defective CD4+ regulatory T cells in active Takayasu arteritis patients can be improved by efficiency treatment of tofacitinib
jing luo¹ and Lan He², ¹the first affiliated hospital of xi'an jiaotong university, xi'an, China (People's Republic), ²The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic)
Background/Purpose: To investigate the efficacy of tofacitinib (TOF) in patients with active TAK, explore the effect on CD4+ regulatory T cells (Tregs) homeostasis and relationship…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].